KYPROLIS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug KYPROLIS contains one active pharmaceutical ingredient (API):

1	Carfilzomib UNII 72X6E3J5AR - CARFILZOMIB
	Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that selectively and irreversibly binds to the N-terminal threonine containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome, and displays little to no activity against other protease classes. Carfilzomib had antiproliferative and proapoptotic activities in preclinical models in haematologic tumours.
	Read more about Carfilzomib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KYPROLIS Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XG02		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors
Discover more medicines within L01XG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11229B, 11230C, 12243J, 12244K
BR	Câmara de Regulação do Mercado de Medicamentos	544116100003701
CA	Health Products and Food Branch	02451034, 02459930, 02459949
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	4764-MEE-0719
EE	Ravimiamet	1703911, 1735680, 1735691
ES	Centro de información online de medicamentos de la AEMPS	1151060001, 1151060002, 1151060003, 115106001IP
FI	Lääkealan turvallisuus- ja kehittämiskeskus	090435, 534401, 542915
FR	Base de données publique des médicaments	62529551, 64296925, 69270884
GB	Medicines & Healthcare Products Regulatory Agency	311435, 345309, 345315, 392404
HK	Department of Health Drug Office	64828, 65431
IL	מִשְׂרַד הַבְּרִיאוּת	7400
IT	Agenzia del Farmaco	044553016, 044553028, 044553030
JP	医薬品医療機器総合機構	4291433D1026, 4291433D2022
LT	Valstybinė vaistų kontrolės tarnyba	1079120, 1082362, 1082363
NL	Z-Index G-Standaard, PRK	129399, 134902, 134910
NZ	Medicines and Medical Devices Safety Authority	19151, 19212
PL	Rejestru Produktów Leczniczych	100359181, 100378132, 100378149
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62506001
SG	Health Sciences Authority	15184P, 15414P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699862270014
US	FDA, National Drug Code	76075-101, 76075-102, 76075-103